Dari Mahrokh Abouali Gale, Vahedian Vahid, Kempisty Bartosz, Morenikeji Olanrewaju B, Farzaneh Maryam, Anbiyaiee Amir
Department of Obstetrics and Gynecology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Department of Hematology, Transfusion Medicine and Cellular Therapy, University of Sao Paulo, Faculty of Medicine, Clinical Hospital (HCFMUSP), Division of Oncology/Hematology, Sao Paulo State Cancer Institute (ICESP), Sao Paulo, Brazil.
Curr Mol Med. 2024 Jun 7. doi: 10.2174/0115665240304247240529074123.
MicroRNAs (miRNAs) have emerged as crucial regulators of gene expression, playing pivotal roles in various biological processes, including cancer development and progression. Among them, miR-125b has garnered significant attention due to its multifaceted functional roles in human hepatocellular carcinoma (HCC). Extensive research has revealed that miR-125b plays a dual role in HCC, acting as both a tumor suppressor and an oncogene depending on the context. As a tumor suppressor, miR-125b exerts its inhibitory effects on HCC by targeting key oncogenic pathways and genes involved in cell proliferation, migration, invasion, and angiogenesis. Its downregulation in HCC is frequently observed and correlates with aggressive tumor characteristics and poor prognosis. Conversely, miR-125b can also function as an oncogene in specific HCC subtypes or under certain conditions. It has been shown to promote HCC growth, metastasis, and therapeutic resistance by targeting tumor suppressor genes, modulating the epithelial-mesenchymal transition (EMT) process, and enhancing cancer stem cell-like properties. The upregulation of miR-125b in HCC has been associated with advanced disease stages and unfavorable clinical outcomes. Furthermore, the dysregulation of miR-125b expression in HCC is influenced by a complex network of regulatory mechanisms. Understanding these regulatory mechanisms is crucial for deciphering the precise functional roles of miR-125b in HCC and exploring its potential as a diagnostic biomarker or therapeutic target. In the current review study, we comprehensively elucidated the diverse functional roles of miR-125b in HCC, providing a comprehensive overview of its regulatory mechanisms and impact on key cellular processes involved in HCC progression.
微小RNA（miRNA）已成为基因表达的关键调节因子，在包括癌症发展和进展在内的各种生物过程中发挥着核心作用。其中，miR-125b因其在人类肝细胞癌（HCC）中的多方面功能作用而备受关注。广泛的研究表明，miR-125b在HCC中发挥双重作用，根据具体情况既可以作为肿瘤抑制因子，也可以作为癌基因。作为肿瘤抑制因子，miR-125b通过靶向参与细胞增殖、迁移、侵袭和血管生成的关键致癌途径和基因，对HCC发挥抑制作用。在HCC中经常观察到其表达下调，并且与侵袭性肿瘤特征和不良预后相关。相反，miR-125b在特定的HCC亚型或某些条件下也可以作为癌基因发挥作用。已证明它通过靶向肿瘤抑制基因、调节上皮-间质转化（EMT）过程以及增强癌症干细胞样特性来促进HCC的生长、转移和治疗耐药性。HCC中miR-125b的上调与疾病晚期和不良临床结果相关。此外，HCC中miR-125b表达的失调受复杂的调节机制网络影响。了解这些调节机制对于解读miR-125b在HCC中的精确功能作用以及探索其作为诊断生物标志物或治疗靶点的潜力至关重要。在当前的综述研究中，我们全面阐述了miR-125b在HCC中的多种功能作用，对其调节机制以及对HCC进展中关键细胞过程的影响进行了全面概述。
